drugset / Trial / NCT04343001

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

NCT04343001

RandomizedFactorialOpen-labelTreatment

Summary

The CRASH-19 trial is a multinational, open-label, factorial, randomised trial in adults hospitalised with suspected or confirmed acute COVID-19 infection.

Timeline

Start
2020-10
Primary completion
2021-04
Completion
2021-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 150 mg
Subject Losartan Other / unclassified 100 mg
Subject Simvastatin Small molecule 80 mg

Indications